Patents Assigned to LYNK PHARMACEUTICALS CO. LTD.
  • Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof
    Patent number: 11981663
    Abstract: The invention provides novel benzamides of pyrazolyl-amino-pyrimidinyl derivatives of Formula (I) as selective and potent JAK inhibitors for treating various diseases and disorders. The invention also provides pharmaceutical composition of these compounds and methods of their preparation and use thereof.
    Type: Grant
    Filed: September 10, 2023
    Date of Patent: May 14, 2024
    Assignee: LYNK PHARMACEUTICALS CO. LTD.
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez, Xiaodong Li
  • Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof
    Patent number: 11858933
    Abstract: The invention provides a novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e.g., inflammatory diseases, immune-mediated diseases or cancer).
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: January 2, 2024
    Assignee: LYNK PHARMACEUTICALS CO. LTD.
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez
  • Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof
    Patent number: 11851431
    Abstract: The invention provides a novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e.g., inflammatory diseases, immune-mediated diseases or cancer).
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: December 26, 2023
    Assignee: LYNK PHARMACEUTICALS CO. LTD.
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez